세계의 무좀 시장 : 질환 유형별, 치료 유형별, 투여 경로별, 유통 채널별, 지역별

Global Athlete's foot Market is estimated to be valued at USD 1.41 Bn in 2025 and is expected to reach USD 1.99 Bn by 2032, growing at a compound annual growth rate (CAGR) of 5.0% from 2025 to 2032.

Figure. Global Athlete's foot Market Share (%), By Region 2025

Athlete's foot, also known as tinea pedis, is a common fungal infection that affects the skin on the feet, particularly the spaces between the toes, but can also spread to the toenails and hands. It is named athlete's foot because it is frequently seen in athletes, as the fungus thrives in warm, moist environments, such as the inside of sweaty shoes, which are common among sports participants. This condition is characterized by itching, stinging, and burning sensations between the toes or on the soles of the feet. The affected skin may also become red, flaky, cracked, or blistered. Although the condition can be uncomfortable, it is generally mild and can be treated with over-the-counter antifungal medications. In persistent or severe cases, prescription-strength treatments may be necessary. Athlete's foot is caused by dermatophytes, a type of fungus that grows on the dead outer layer of skin. The fungus spreads easily through direct contact with contaminated surfaces or through indirect contact with towels, shoes, or clothing. Communal showers, swimming pools, and locker rooms are hotspots for transmission, making athletes and gym-goers particularly susceptible. Good foot hygiene plays a crucial role in preventing athlete's foot. This includes keeping the feet clean and dry, wearing breathable footwear, changing socks regularly, and avoiding walking barefoot in public places where the fungus may be present. Individuals with athlete's foot should also be careful not to spread the infection to other parts of their body or to other people. Early detection and treatment of athlete's foot are important to prevent the infection from becoming more difficult to manage or leading to more serious secondary bacterial infections. Understanding the causes, prevention, and treatment options enables individuals to effectively deal with this condition and maintain good foot health.

Market Dynamics:

The global athlete's foot market is primarily driven by the rising prevalence of the infection due to a growing geriatric population, increasing obesity rates, and greater participation in aquatic activities. Growing health awareness regarding implications of untreated fungal infections of feet is also supporting self-diagnosis and over-the-counter medication. However, alternative treatment options such as home remedies using over-the-counter (OTC) topical creams and powders may hinder revenue generation potential for prescription drugs.

Key features of the study:

• This report provides in-depth analysis of the global athlete's foot market, and provides market size (US$ Bn) and compound annual growth rate (CAGR %) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global athlete's foot market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Perrigo Company Plc., Novartis AG, Valeant Pharmaceuticals International, GlaxoSmithKline plc, Bayer AG, Teva Pharmaceuticals Industries Ltd., Mylan NV, Glenmark Pharmaceutical Ltd, Taro Pharmaceutical Industries Ltd., Camber Pharmaceuticals Inc, Aurobindo Pharma Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global athlete's foot market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global athlete's foot market

Detailed Segmentation:

• Global Athlete's Foot Market, By Drug Class
  • Antifungals
  • Combination
• Global Athlete's Foot Market, By Disease Indication
  • Interdigital
  • Plantar
  • Vesicular
• Global Athlete's Foot Market, By Route of Administration
  • Topical
  • Oral
• Global Athlete's Foot Market, By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Athlete's Foot Market, By Region
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
• Company Profiles
  • Perrigo Company Plc.
  • Novartis AG
  • Valeant Pharmaceuticals International
  • GlaxoSmithKline plc
  • Bayer AG
  • Teva Pharmaceuticals Industries Ltd.
  • Mylan NV
  • Glenmark Pharmaceutical Ltd
  • Taro Pharmaceutical Industries Ltd.
  • Camber Pharmaceuticals Inc
  • Aurobindo Pharma Ltd

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Athlete's Foot, By Drug Class
  • Market Athlete's Foot, By Disease Indication
  • Market Athlete's Foot, By Route of Administration
  • Market Athlete's Foot, By Distribution Channel
  • Market Athlete's Foot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Driver
• Growing health and hygiene awareness
• Increasing spending on personal care and sports healthcare
• Technological advancements in treatment options
• Key Highlights
• Regulatory Scenario
• Recent Trends
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Mergers, Acquisitions, and Collaborations

4. Global Athlete's Foot Market- Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Global Athlete's Foot Market, By Drug Class, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Antifungals
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Combination
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

6. Global Athlete's Foot Market, By Disease Indication, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021-2032
  • Segment Trends
• Interdigital
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Plantar
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Vesicular
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

7. Global Athlete's Foot Market, By Route of Administration, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2021-2032
  • Segment Trends
• Topical
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

8. Global Athlete's Foot Market, By Distribution Channel, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2021-2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

9. Global Athlete's Foot Market, By Region, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, By Country, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Country 2020 -2032
  • Country Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
    • U.S.
    • Canada
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032,(US$ Bn)
    • South Africa
    • North Africa
    • Central Africa

10. Competitive Landscape

• Company Profile
  • Perrigo Company Plc.
• Drug Class Portfolio
• Key Developments
• Financial Performance
• Strategies
  • Novartis AG
• Drug Class Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Valeant Pharmaceuticals International
• Drug Class Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • GlaxoSmithKline plc
• Company Highlights
• Drug Class Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Bayer AG
• Company Highlights
• Drug Class Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Teva Pharmaceuticals Industries Ltd.
• Company Highlights
• Drug Class Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Mylan NV
• Company Highlights
• Drug Class Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Glenmark Pharmaceutical Ltd
• Company Highlights
• Drug Class Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Taro Pharmaceutical Industries Ltd.
• Company Highlights
• Drug Class Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Camber Pharmaceuticals Inc
• Company Highlights
• Drug Class Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Aurobindo Pharma Ltd
• Company Highlights
• Drug Class Portfolio
• Key Highlights
• Financial Performance
• Strategies
• Analyst Views

11. Section

• References
• Research Methodology
• About us